Bcl-2 Allostery & Resistance Dynamics
Targeted oncology therapies like venetoclax frequently encounter acquired resistance through mutations in the BH3 groove (such as G101V). Our computational campaign investigates whether rare rice-derived diol scaffolds can engage alternative back-face surfaces on Bcl-2 to bypass groove-specific resistance.
- Planned SPR kinetic binding screens at Reaction Biology
- Analytical LC-MS release kinetics at USF CPAS core
- Focus: Chronic lymphocytic leukemia (CLL) models